Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants - Takeaways - MDSpire

Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

  • By

  • Ilker Nihat Ökten

  • Tuba Baydaş

  • Sinan Koca

  • Mukaddes Feyza Baltacı

  • Filiz Özen

  • İbrahim Çil

  • Metin Eser

  • Adnan Gündoğdu

  • Merve Aktaş

  • Osman Cem Yılmaz

  • February 13, 2026

  • 0 min

Share

  • 1

    Breast cancer is the most common malignancy and a leading cause of cancer-related mortality among women globally, with over 2.3 million new cases in 2022.

  • 2

    Pathogenic BRCA1/2 variants significantly increase breast cancer risk, with a lifetime risk of 45% to 75%, necessitating tailored clinical management.

  • 3

    Variants of uncertain significance (VUS) in BRCA1/2 complicate clinical decision-making, as their pathogenicity is often unclear at the time of detection.

  • 4

    This study analyzed surgical management patterns in breast cancer patients with pathogenic BRCA variants versus those with VUS across three Turkish centers.

  • 5

    The research highlights the need for improved guidance in surgical decision-making for patients with BRCA VUS, given the rising prevalence of genetic testing.

Original Source(s)

Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

  • by Ilker Nihat Ökten, Tuba Baydaş, Sinan Koca, Mukaddes Feyza Baltacı, Filiz Özen, İbrahim Çil, Metin Eser, Adnan Gündoğdu, Merve Aktaş, Osman Cem Yılmaz

  • February 13, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2